l General Information |
Product Name | Panobinostat |
General description | Panobinostat, a cinnamic hydroxamic acid analogue, is a novel broad-spectrum inhibitor of HDAC with potential antineoplastic activity. |
Synonym | (E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide; LBH-589; LBH589; Farydak; |
Purity | ≥98%(HPLC) | CAS Number | 404950-80-7 |
Formula | C21H23N3O2 | Molecular Weight | 349.434 |
Suitability | BioReagent, suitable for cell culture, etc. |
l Physical and Chemical Information |
Appearance | White or Off-white solid |
Solubility(25℃) | DMSO | ≥50mg/mL |
Ethanol | Insoluble |
Water | Insoluble |
l Biological Information |
Biochem/Physiol Actions | Panobinostat is a cinnamic hydroxamic acid analogue with potential antineoplastic activity. Panobinostat selectively inhibits histone deacetylase (HDAC), inducing hyperacetylation of core histone proteins, which may result in modulation of cell cycle protein , cell cycle arrest in the G2/M phase and apoptosis. In addition, this agent appears to modulate the of angiogenesis-related genes, such as hypoxia-inducible factor-1alpha (HIF-1a) and vascular endothelial growth factor (VEGF), thus impairing endothelial cell chemotaxis and invasion. HDAC is an enzyme that deacetylates chromatin histone proteins. |
Application | 1. Antineoplastic Agents 2. Histone Deacetylase Inhibitors |
l Packaging & Storage |
Packaging | 5mg; 25mg; 100mg |
Storage temp. | -20℃ |
l Precautions and Disclaimer |
This product is for R&D use only, not for drug, household, or other uses. |
l References |
1. http://www.drugbank.ca 2. https://ncit.nci.nih.gov 3. https://www.ncbi.nlm.nih.gov |
